Half-Life (Normalesrd) Hours
7-9/No change
Plasma Protein Binding %
96
Volume Of Distribution L/Kg
0.9-1.7
Dose For Normal Renal Function
4 mg qd
Second Dose
Second Dose: Increase by 4 mg/day, titrate dose weekly
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [A]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
100% [A]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
100% [A]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None, [A]
Supplement For Dialysis [Recommendation Level]: Pd
PD: None, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: No data, [D]
References
Bourgeois BF. Pharmacokinetic properties of current antiepileptic drugs: what improvements are needed? Neurology. 2000; 55: S11-6. [PMID: 11147563] / Ingwersen SH, Pedersen PC, Groes L, Nielsen KK, Aarons L. Population pharmacokinetics of tiagabine in epileptic patients on monotherapy. Eur J Pharm Sci. 2000; 11: 247-54. [PMID: 11042231]
Toxicity Notes
Total daily dose may be increased by 4 to 8 mg at weekly intervals until clinical response is achieved or up to 32 mg/day. Total daily dose should be given in divided doses two to four times daily.